BioAge Labs, Inc.
BioAge Labs, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||
Cash And Cash Equivalents At Carrying Value | 242 | 189 | 216 | 220 | 257 | 354 | 334 | |||||
Marketable Securities Current | 141 | 92 | 70 | 77 | 63 | 0 | - | |||||
Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 0 | 0 | - | |||||
Prepaid Expense And Other Assets Current | 8 | 5 | 5 | 4 | 4 | 3 | 2 | |||||
Assets Current | 392 | 287 | 291 | 302 | 325 | 357 | 336 | |||||
Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Marketable Securities | 2 | 4 | 10 | 16 | 15 | 0 | - | |||||
Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 3 | 0 | 0 | |||||
Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Assets | 398 | 295 | 305 | 322 | 344 | 358 | 337 | |||||
Liabilities | ||||||||||||
Liabilities Current | ||||||||||||
Accounts Payable Current | 3 | 3 | 5 | 1 | 4 | 2 | 2 | |||||
Long Term Debt Current | 1 | 3 | 4 | 6 | 6 | 6 | 6 | |||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |||||
Contract With Customer Liability Current | 6 | 6 | 8 | 8 | 8 | 8 | - | |||||
Liabilities Current | 16 | 20 | 24 | 23 | 24 | 28 | 19 | |||||
Contract With Customer Liability Noncurrent | - | 0 | 1 | 2 | 3 | 5 | - | |||||
Long Term Debt Noncurrent | - | 0 | 0 | 0 | 1 | 3 | 4 | |||||
Derivative Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Operating Lease Liability Noncurrent | 2 | 2 | 2 | 3 | 3 | 0 | - | |||||
Liabilities | 19 | 23 | 28 | 27 | 31 | 35 | 24 | |||||
Temporary Equity Carrying Amount Attributable To P… | - | 0 | - | - | - | 0 | 0 | |||||
Stockholders Equity | ||||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Common Stock Value | 0 | 0 | 0 | 0 | - | 0 | - | |||||
Additional Paid In Capital | 735 | 605 | 585 | 582 | 579 | 576 | 545 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | -356 | -333 | -307 | -287 | -266 | -253 | -232 | |||||
Stockholders Equity | 379 | 272 | 277 | 295 | 313 | 323 | 314 | |||||
Liabilities And Stockholders Equity | 398 | 295 | 305 | 322 | 344 | 358 | 337 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | 0 | 0 | |||||
Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | |||||
Common Stock Shares Issued | 44 | 37 | 36 | 36 | 36 | 36 | 34 | |||||
Temporary Equity Shares Issued | - | - | - | - | - | 0 | 0 | |||||
Shares Outstanding | 44 | 37 | 36 | 36 | 36 | 36 | 34 | |||||
Temporary Equity Shares Outstanding | - | - | - | - | - | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.89% | 32.07% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 0.25% | 6.33% | 16.96% | 13.86% | 25.17% | 75.52% | 27.04% | 85.81% | 151.81% | 14.77% | 9.62% | 11.98% |
| 2024 | - | - | - | - | - | - | -8.83% | -73.33% | -73.81% | -15.98% | -7.76% | 1.60% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
BioAge Labs, Inc. (BIOA) — SEC Financial Statements & Analysis
BioAge Labs, Inc. (BIOA) is a pharmaceutical preparations company, incorporated in DE. BioAge Labs, Inc. trades on Nasdaq as: BIOA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BioAge Labs, Inc. reported a Debt-to-Equity ratio of 0.05x, a Price-to-Sales (P/S) ratio of 72.02x (TTM), a Price-to-Book (P/B) ratio of 1.96 (TTM), at a market cap of $742.98M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.05x
- P/S TTM
- 72.02x
- P/B TTM
- 1.96
- Market Cap
- $742.98M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioAge Labs, Inc. in?
BioAge Labs, Inc. (BIOA) operates in the Pharmaceutical Preparations industry.
What is BIOA's market cap?
BioAge Labs, Inc. (BIOA) has a market capitalization of $742.98M as of 2026-03-31.
What exchange does BIOA trade on?
BioAge Labs, Inc. (BIOA) trades on the Nasdaq.
Where is BioAge Labs, Inc. incorporated?
BioAge Labs, Inc. is incorporated in DE.